Gene Therapy for Male Erectile Dysfunction

Arnold Melman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The potential clinical advantages of a gene transfer therapy-based approach to treatment of genitourinary smooth muscle-based disorders are several: potential single therapy for restoration of normal bladder or erectile function; eliminating the need for daily medication; use in combination with other therapies to reduce dose requirements and side effects; and development of mechanism-based, patient-specific treatment approaches. With the safe administration of hMax-K to men with erectile dysfunction in the first human phase 1 trial and the initiation of the phase 1 trial of hMaxi-K for patients who have detrusor overactivity, we have entered an exciting new era in the development of safe enduring therapies for genitourinary disorders.

Original languageEnglish (US)
Pages (from-to)619-630
Number of pages12
JournalUrologic Clinics of North America
Volume34
Issue number4
DOIs
StatePublished - Nov 2007

Fingerprint

Erectile Dysfunction
Genetic Therapy
Therapeutics
Muscular Diseases
Smooth Muscle
Urinary Bladder

ASJC Scopus subject areas

  • Urology

Cite this

Gene Therapy for Male Erectile Dysfunction. / Melman, Arnold.

In: Urologic Clinics of North America, Vol. 34, No. 4, 11.2007, p. 619-630.

Research output: Contribution to journalArticle

Melman, Arnold. / Gene Therapy for Male Erectile Dysfunction. In: Urologic Clinics of North America. 2007 ; Vol. 34, No. 4. pp. 619-630.
@article{6f5e332378f44ed388f0595c90c1e533,
title = "Gene Therapy for Male Erectile Dysfunction",
abstract = "The potential clinical advantages of a gene transfer therapy-based approach to treatment of genitourinary smooth muscle-based disorders are several: potential single therapy for restoration of normal bladder or erectile function; eliminating the need for daily medication; use in combination with other therapies to reduce dose requirements and side effects; and development of mechanism-based, patient-specific treatment approaches. With the safe administration of hMax-K to men with erectile dysfunction in the first human phase 1 trial and the initiation of the phase 1 trial of hMaxi-K for patients who have detrusor overactivity, we have entered an exciting new era in the development of safe enduring therapies for genitourinary disorders.",
author = "Arnold Melman",
year = "2007",
month = "11",
doi = "10.1016/j.ucl.2007.08.005",
language = "English (US)",
volume = "34",
pages = "619--630",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Gene Therapy for Male Erectile Dysfunction

AU - Melman, Arnold

PY - 2007/11

Y1 - 2007/11

N2 - The potential clinical advantages of a gene transfer therapy-based approach to treatment of genitourinary smooth muscle-based disorders are several: potential single therapy for restoration of normal bladder or erectile function; eliminating the need for daily medication; use in combination with other therapies to reduce dose requirements and side effects; and development of mechanism-based, patient-specific treatment approaches. With the safe administration of hMax-K to men with erectile dysfunction in the first human phase 1 trial and the initiation of the phase 1 trial of hMaxi-K for patients who have detrusor overactivity, we have entered an exciting new era in the development of safe enduring therapies for genitourinary disorders.

AB - The potential clinical advantages of a gene transfer therapy-based approach to treatment of genitourinary smooth muscle-based disorders are several: potential single therapy for restoration of normal bladder or erectile function; eliminating the need for daily medication; use in combination with other therapies to reduce dose requirements and side effects; and development of mechanism-based, patient-specific treatment approaches. With the safe administration of hMax-K to men with erectile dysfunction in the first human phase 1 trial and the initiation of the phase 1 trial of hMaxi-K for patients who have detrusor overactivity, we have entered an exciting new era in the development of safe enduring therapies for genitourinary disorders.

UR - http://www.scopus.com/inward/record.url?scp=35649004407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649004407&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2007.08.005

DO - 10.1016/j.ucl.2007.08.005

M3 - Article

VL - 34

SP - 619

EP - 630

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 4

ER -